A phase II study of 13-cis retinoic acid plus interferon α-2a in advanced stage penile carcinoma

An Eastern Cooperative Oncology Group Study (E3893)#

Roland T. Skeel, Jie Huang, Judith Manola, George Wilding, Robert Dreicer, Paul Walker, Franco Muggia, E. David Crawford, Janice P. Dutcher, Patrick Loehrer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose. Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN α-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin. Squamous cell carcinoma of the penis is rare in the United States, accounting for less than 1/2% of all male malignancies. Because of the association of infection with human papillomavirus with both carcinomas of the cervix and penis and their shared squamous cell histology, we carried out a phase II study of 13cRA and IFN α-2a in carcinoma of the penis. Materials and Methods. Eighteen ambulatory patients with surgically unresectable, recurrent, and/or metastatic squamous cell carcinoma of the penis were treated with IFN α-2a, 3MU/day administered subcutaneously and 13-cRA, 1 mg/kg orally daily for at least eight weeks, unless intolerable toxicity occurred. Results. One patient was ineligible; one patient withdrew prior to treatment. Among the 16 eligible, treated patients, there was one complete response. Fourteen patients had progressive disease as their only treatment effect. Two patients were unevaluable for tumor response because they had no follow-up tumor measurements. No unexpected treatment-related toxicities were found on study. The only common form of grade 3 toxicity was hypertriglyceridemia found in eight of the 17 patients (47%). No toxicities above grade 3 were observed. Conclusion. In contrast to its benefit in squamous cell carcinomas of the cervix and skin, the combination of 13-cRA and IFN α-2a has low efficacy in advanced carcinoma of the penis.

Original languageEnglish
Pages (from-to)41-46
Number of pages6
JournalCancer Investigation
Volume21
Issue number1
DOIs
StatePublished - 2003

Fingerprint

Isotretinoin
Interferons
Penis
Carcinoma
Squamous Cell Carcinoma
Cervix Uteri
Neoplasms
Skin
Biological Therapy
Hypertriglyceridemia
Histology
Therapeutics
Epithelial Cells
interferon alfa-2a
Infection

Keywords

  • Clinical trials
  • Interferon alpha-2a
  • Penile neoplasms
  • Tretinoin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II study of 13-cis retinoic acid plus interferon α-2a in advanced stage penile carcinoma : An Eastern Cooperative Oncology Group Study (E3893)#. / Skeel, Roland T.; Huang, Jie; Manola, Judith; Wilding, George; Dreicer, Robert; Walker, Paul; Muggia, Franco; Crawford, E. David; Dutcher, Janice P.; Loehrer, Patrick.

In: Cancer Investigation, Vol. 21, No. 1, 2003, p. 41-46.

Research output: Contribution to journalArticle

Skeel, Roland T. ; Huang, Jie ; Manola, Judith ; Wilding, George ; Dreicer, Robert ; Walker, Paul ; Muggia, Franco ; Crawford, E. David ; Dutcher, Janice P. ; Loehrer, Patrick. / A phase II study of 13-cis retinoic acid plus interferon α-2a in advanced stage penile carcinoma : An Eastern Cooperative Oncology Group Study (E3893)#. In: Cancer Investigation. 2003 ; Vol. 21, No. 1. pp. 41-46.
@article{1c8c93816d0e46df8adba06ae7d0116c,
title = "A phase II study of 13-cis retinoic acid plus interferon α-2a in advanced stage penile carcinoma: An Eastern Cooperative Oncology Group Study (E3893)#",
abstract = "Purpose. Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN α-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin. Squamous cell carcinoma of the penis is rare in the United States, accounting for less than 1/2{\%} of all male malignancies. Because of the association of infection with human papillomavirus with both carcinomas of the cervix and penis and their shared squamous cell histology, we carried out a phase II study of 13cRA and IFN α-2a in carcinoma of the penis. Materials and Methods. Eighteen ambulatory patients with surgically unresectable, recurrent, and/or metastatic squamous cell carcinoma of the penis were treated with IFN α-2a, 3MU/day administered subcutaneously and 13-cRA, 1 mg/kg orally daily for at least eight weeks, unless intolerable toxicity occurred. Results. One patient was ineligible; one patient withdrew prior to treatment. Among the 16 eligible, treated patients, there was one complete response. Fourteen patients had progressive disease as their only treatment effect. Two patients were unevaluable for tumor response because they had no follow-up tumor measurements. No unexpected treatment-related toxicities were found on study. The only common form of grade 3 toxicity was hypertriglyceridemia found in eight of the 17 patients (47{\%}). No toxicities above grade 3 were observed. Conclusion. In contrast to its benefit in squamous cell carcinomas of the cervix and skin, the combination of 13-cRA and IFN α-2a has low efficacy in advanced carcinoma of the penis.",
keywords = "Clinical trials, Interferon alpha-2a, Penile neoplasms, Tretinoin",
author = "Skeel, {Roland T.} and Jie Huang and Judith Manola and George Wilding and Robert Dreicer and Paul Walker and Franco Muggia and Crawford, {E. David} and Dutcher, {Janice P.} and Patrick Loehrer",
year = "2003",
doi = "10.1081/CNV-120016402",
language = "English",
volume = "21",
pages = "41--46",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - A phase II study of 13-cis retinoic acid plus interferon α-2a in advanced stage penile carcinoma

T2 - An Eastern Cooperative Oncology Group Study (E3893)#

AU - Skeel, Roland T.

AU - Huang, Jie

AU - Manola, Judith

AU - Wilding, George

AU - Dreicer, Robert

AU - Walker, Paul

AU - Muggia, Franco

AU - Crawford, E. David

AU - Dutcher, Janice P.

AU - Loehrer, Patrick

PY - 2003

Y1 - 2003

N2 - Purpose. Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN α-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin. Squamous cell carcinoma of the penis is rare in the United States, accounting for less than 1/2% of all male malignancies. Because of the association of infection with human papillomavirus with both carcinomas of the cervix and penis and their shared squamous cell histology, we carried out a phase II study of 13cRA and IFN α-2a in carcinoma of the penis. Materials and Methods. Eighteen ambulatory patients with surgically unresectable, recurrent, and/or metastatic squamous cell carcinoma of the penis were treated with IFN α-2a, 3MU/day administered subcutaneously and 13-cRA, 1 mg/kg orally daily for at least eight weeks, unless intolerable toxicity occurred. Results. One patient was ineligible; one patient withdrew prior to treatment. Among the 16 eligible, treated patients, there was one complete response. Fourteen patients had progressive disease as their only treatment effect. Two patients were unevaluable for tumor response because they had no follow-up tumor measurements. No unexpected treatment-related toxicities were found on study. The only common form of grade 3 toxicity was hypertriglyceridemia found in eight of the 17 patients (47%). No toxicities above grade 3 were observed. Conclusion. In contrast to its benefit in squamous cell carcinomas of the cervix and skin, the combination of 13-cRA and IFN α-2a has low efficacy in advanced carcinoma of the penis.

AB - Purpose. Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN α-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin. Squamous cell carcinoma of the penis is rare in the United States, accounting for less than 1/2% of all male malignancies. Because of the association of infection with human papillomavirus with both carcinomas of the cervix and penis and their shared squamous cell histology, we carried out a phase II study of 13cRA and IFN α-2a in carcinoma of the penis. Materials and Methods. Eighteen ambulatory patients with surgically unresectable, recurrent, and/or metastatic squamous cell carcinoma of the penis were treated with IFN α-2a, 3MU/day administered subcutaneously and 13-cRA, 1 mg/kg orally daily for at least eight weeks, unless intolerable toxicity occurred. Results. One patient was ineligible; one patient withdrew prior to treatment. Among the 16 eligible, treated patients, there was one complete response. Fourteen patients had progressive disease as their only treatment effect. Two patients were unevaluable for tumor response because they had no follow-up tumor measurements. No unexpected treatment-related toxicities were found on study. The only common form of grade 3 toxicity was hypertriglyceridemia found in eight of the 17 patients (47%). No toxicities above grade 3 were observed. Conclusion. In contrast to its benefit in squamous cell carcinomas of the cervix and skin, the combination of 13-cRA and IFN α-2a has low efficacy in advanced carcinoma of the penis.

KW - Clinical trials

KW - Interferon alpha-2a

KW - Penile neoplasms

KW - Tretinoin

UR - http://www.scopus.com/inward/record.url?scp=0037215025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037215025&partnerID=8YFLogxK

U2 - 10.1081/CNV-120016402

DO - 10.1081/CNV-120016402

M3 - Article

VL - 21

SP - 41

EP - 46

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 1

ER -